The gut is the largest endocrine organ in the body. Hundreds of distinct enteroendocrine cells lining the stomach, small intestine, and colon release peptide hormones that coordinate digestion, nutrient absorption, insulin secretion, appetite, motility, and communication with the central nervous system. Twenty years ago these peptides were treated largely as curiosities of physiology textbooks. Today they are the center of gravity in metabolic medicine — the GLP-1 and GIP receptor agonists alone represent a pharmaceutical category projected to exceed $100 billion in annual revenue by the late 2020s.
This guide covers six of the most pharmacologically and clinically important gut and metabolic hormones: motilin, secretin, peptide YY (PYY), glucose-dependent insulinotropic peptide (GIP), nesfatin-1, and glucagon. Some have FDA-approved therapeutic analogs (glucagon as a rescue medication; GIP as half of tirzepatide). Others are research targets whose therapeutic potential is still being mapped (PYY, nesfatin-1). One — secretin — holds a historical distinction as the first hormone ever discovered, even if its clinical role today is narrow.
The guide emphasizes mechanism, physiological role, and where each peptide sits on the spectrum from textbook curiosity to commercial blockbuster. It does not recommend self-administration of any of these peptides outside of FDA-approved, prescription-channel products. Research-grade peptide use for self-experimentation is common in online communities, but gut hormones are tightly integrated with insulin secretion, blood pressure, and motility — and thus carry risks that are not well characterized at the doses used off-label.
For individual pharmacology, dosing, and trial detail, see each peptide's PeptaHub profile.
Gut-brain axis intro — why gut hormones matter
The gut-brain axis describes the bidirectional communication between the gastrointestinal tract and the central nervous system. It runs along three parallel channels: the vagus nerve, which carries mechanoreceptor and chemoreceptor signals from the gut lumen to the brainstem; the enteric nervous system, sometimes called the "second brain," which contains more neurons than the spinal cord and can operate semi-autonomously; and the endocrine channel, in which enteroendocrine cells release peptide hormones that travel via the bloodstream to act on distant organs, including the hypothalamus and brainstem nuclei that regulate appetite and energy balance.
Gut hormones are the chemical language of that endocrine channel. They are released in response to specific luminal stimuli — nutrients, pH changes, distension, microbial metabolites — and act on G-protein-coupled receptors expressed on target tissues. GLP-1, GIP, PYY, ghrelin, motilin, secretin, cholecystokinin, and oxyntomodulin are among the most-studied members of this family. Each has a distinct triggering stimulus and a distinct downstream effect, and together they coordinate the temporal sequence of digestion.
The therapeutic relevance comes from the discovery that pharmacologically amplifying some of these signals produces striking metabolic effects. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and GIP/GLP-1 dual agonists (tirzepatide) have demonstrated 15–23% mean weight loss in Phase 3 obesity trials and cardiovascular protection in randomized trials of tens of thousands of patients. The gut hormones covered in this guide sit in this broader context — some already therapeutic, others still moving through translation.
Motilin — Phase III MMC contractions and the erythromycin connection
Motilin is a 22-amino-acid peptide secreted by M-cells in the duodenum and proximal jejunum during fasting. Its defining role is the initiation of Phase III contractions of the migrating motor complex (MMC), the stereotyped "housekeeper" contraction wave that sweeps undigested debris and bacteria from the stomach and small intestine between meals. Motilin concentrations rise in pulses approximately every 90–120 minutes during fasting, triggering each MMC cycle; the rhythm is suppressed by eating and resumes once the stomach empties.
The clinical significance of motilin came into focus with the observation that the macrolide antibiotic erythromycin is a potent motilin receptor agonist. At sub-antibiotic doses, erythromycin accelerates gastric emptying and is used off-label for gastroparesis, post-surgical ileus, and as a prokinetic before gastric endoscopy. Tachyphylaxis — the loss of response after repeated dosing — limits long-term use. Several synthetic motilin receptor agonists, including camicinal, have been developed to provide sustained prokinetic benefit without antibiotic effects, but as of 2026 none have reached widespread FDA approval for gastroparesis.
Motilin itself is a research peptide, not a therapeutic. It is used in physiology studies to probe gastric motility and in pharmacology research as a reference ligand for motilin receptor assays. Self-administered motilin is not a recognized therapeutic practice.
Secretin — the first hormone ever discovered (Bayliss & Starling, 1902)
Secretin holds a specific place in medical history: it was the first hormone ever described, identified by William Bayliss and Ernest Starling in 1902. Their experiments showed that an extract of duodenal mucosa injected intravenously caused pancreatic secretion, proving that chemical signals could coordinate organ function across the body without neural connections. Starling coined the term "hormone" from the Greek hormao, meaning "to arouse," a few years later.
Secretin is a 27-amino-acid peptide released from S-cells in the duodenum in response to acidic chyme (pH below about 4.5) entering from the stomach. It signals through the secretin receptor on pancreatic ductal cells to stimulate bicarbonate-rich fluid secretion, neutralizing the acidic load and protecting the duodenal mucosa. It also modestly inhibits gastric acid secretion, promotes biliary bicarbonate release, and suppresses gastric emptying.
Its modern clinical use is narrow. Synthetic human secretin (ChiRhoStim) is FDA-approved as a diagnostic agent for the secretin-enhanced MRCP (magnetic resonance cholangiopancreatography) and for the secretin stimulation test used to diagnose pancreatic exocrine insufficiency and gastrinoma (Zollinger-Ellison syndrome). It is administered intravenously as a brief bolus under clinical supervision. Early 2000s investigations into secretin as a treatment for autism were not supported by subsequent randomized trials, and that indication is not pursued. Therapeutic use outside the diagnostic context is not established.
GIP — the incretin half of tirzepatide's success
Glucose-dependent insulinotropic peptide (GIP) is a 42-amino-acid incretin hormone secreted by K-cells in the duodenum and proximal jejunum in response to glucose and fat ingestion. Along with GLP-1, it is one of the two major incretins — hormones that augment insulin secretion from pancreatic beta-cells specifically in the setting of elevated glucose, accounting for roughly 50–70% of the insulin response to an oral meal. Without incretins, a glucose tolerance test with IV glucose produces substantially less insulin than the same glucose load given orally.
GIP signals through the GIPR receptor, a G-protein-coupled receptor expressed on pancreatic beta-cells, adipocytes, bone, and specific brain regions. For decades, GIP was considered the less-interesting incretin for drug development, because GIPR signaling in type 2 diabetes appeared blunted compared with GLP-1 signaling, and GIP had shown mild weight-promoting effects in some preclinical models. This assumption was overturned by tirzepatide (Mounjaro, Zepbound), a unimolecular GIP/GLP-1 dual agonist that combines both activities in a single 39-amino-acid modified peptide. SURPASS and SURMOUNT Phase 3 trials demonstrated superior glycemic and weight-loss outcomes to GLP-1 monotherapy, and tirzepatide is now a leading metabolic therapeutic.
The mechanistic reason GIP agonism contributes to tirzepatide's efficacy remains an active research question. Proposed mechanisms include enhanced beta-cell glucose-responsiveness, CNS effects on appetite, and favorable remodeling of adipose tissue. Standalone GIP receptor agonists are in development, and GIP receptor antagonists are also being tested as an alternative route to weight loss.
PYY3-36 — the ileal brake and satiety signaling
Peptide YY (PYY) is a 36-amino-acid hormone secreted primarily from L-cells in the distal small intestine and colon in response to nutrient ingestion — with fat and protein being the strongest stimuli. Full-length PYY1-36 is cleaved by dipeptidyl peptidase-4 (DPP-4) to produce PYY3-36, the physiologically dominant circulating form. PYY3-36 binds preferentially to the Y2 receptor and produces two major effects: a "ileal brake" that slows gastric emptying and intestinal transit, giving time for nutrient absorption, and a central satiety signal that acts on the arcuate nucleus of the hypothalamus to reduce appetite.
Exogenous PYY3-36 has been studied extensively as a candidate obesity therapeutic. Small clinical studies demonstrated that intravenous or subcutaneous PYY3-36 reduced food intake in lean and obese subjects, but the effect is modest as monotherapy and the peptide causes dose-limiting nausea, which has held back single-agent development. Oral and nasal formulations have been explored with mixed success.
The future of PYY in metabolic medicine is most likely as a combination agent. Co-administration of PYY3-36 with GLP-1 has shown synergistic appetite suppression in experimental human studies. Several fixed-ratio and unimolecular multi-agonist candidates that incorporate PYY activity are in preclinical and early clinical development, alongside the GLP-1/GIP, GLP-1/glucagon, and GLP-1/GIP/glucagon triple agonists that dominate the pipeline. As of 2026, no standalone PYY-based therapeutic is FDA-approved.
Nesfatin-1 — a newer satiety peptide still being mapped
Nesfatin-1 is an 82-amino-acid peptide derived from the precursor protein NUCB2 (nucleobindin-2). It was identified in 2006 by Japanese researchers Oh-I, Shimizu, and colleagues, making it one of the most recently characterized major satiety peptides. Nesfatin-1 is expressed in hypothalamic nuclei — particularly the paraventricular, arcuate, and lateral hypothalamic areas — and in gastric X/A-like cells, where it is co-produced with ghrelin but released under opposite signals: fed versus fasted.
Central administration of nesfatin-1 in rodents suppresses food intake in a leptin-independent manner, distinguishing it from most other anorexigenic hormones. The peripheral receptor for nesfatin-1 has not yet been definitively identified, which has slowed translational pharmacology — a striking gap for a hormone that has been studied for nearly 20 years. Preclinical data also suggests nesfatin-1 has effects on glucose homeostasis, insulin secretion, blood pressure, anxiety-like behavior, and reproductive function, though the mechanistic picture is still being assembled.
Human research has measured circulating nesfatin-1 concentrations in obesity, diabetes, eating disorders, polycystic ovary syndrome, and pregnancy with varying results. No therapeutic agonist or antagonist has reached late-stage clinical trials as of 2026. For now, nesfatin-1 is an intriguing but early-stage target — a reminder that the enteroendocrine system is not fully inventoried, and that new satiety signals continue to emerge.
Glucagon — counter-regulation, rescue kits, and the triple-agonist angle
Glucagon is a 29-amino-acid peptide secreted by pancreatic alpha-cells in response to low blood glucose, exercise, and amino acids. It is the primary counter-regulatory hormone to insulin, mobilizing glucose through hepatic glycogenolysis and gluconeogenesis. Glucagon signals through the GCGR receptor, a class B GPCR highly expressed on hepatocytes. Elevated glucagon is a pathological feature of type 2 diabetes — fasting hyperglucagonemia contributes to hepatic glucose overproduction — and suppression of glucagon secretion is one of the mechanisms by which GLP-1 agonists lower fasting glucose.
Glucagon has long-standing FDA approval as a rescue therapy for severe hypoglycemia, historically administered by caregivers via intramuscular injection of reconstituted lyophilized powder. Modern ready-to-use formulations have greatly simplified this: intranasal glucagon (Baqsimi) delivers a fixed dose through a nasal applicator without requiring reconstitution, and ready-to-inject formulations (Gvoke) provide a similar simplification for subcutaneous delivery. These have significantly improved the practical accessibility of rescue therapy for patients with insulin-treated diabetes.
Glucagon's second life is in combination metabolic therapeutics. Paradoxically, partial glucagon receptor agonism — despite raising blood glucose in the short term — produces net weight loss and improved lipid profiles in multi-agonist constructs through increased energy expenditure and hepatic lipid oxidation. Several GLP-1/glucagon dual agonists (cotadutide, survodutide, pemvidutide, mazdutide) and triple agonists (retatrutide, which adds GIP agonism) are in advanced development for obesity, metabolic dysfunction-associated steatohepatitis, and type 2 diabetes. The glucagon arm is now one of the most strategic components of next-generation metabolic polypharmacy.
Therapeutic angles and the broader gut-hormone pipeline
Looking across the six hormones covered here, the therapeutic momentum is clearly concentrated in the incretin and counter-regulatory space: GIP and glucagon, in combination with GLP-1, have transformed obesity and diabetes medicine over the past five years and continue to drive pipeline innovation. Standalone PYY-based therapeutics remain elusive, but PYY activity is increasingly built into multi-agonist designs. Motilin agonists continue to be pursued for gastroparesis despite tachyphylaxis challenges. Secretin's role is durably diagnostic. Nesfatin-1 remains pre-clinical.
For anyone tracking the gut-hormone field, the practical watchlist in 2026 is: retatrutide's Phase 3 readouts in obesity (GLP-1/GIP/glucagon triple agonist); the emergence of oral GLP-1 and multi-agonist small molecules; the next generation of motilin agonists without tachyphylaxis; and whether a genuine nesfatin-1 receptor identification unlocks that pathway pharmacologically. The gut is still a fertile therapeutic target — not because we have run out of biology, but because we have barely begun to exploit what we have mapped.
Frequently asked questions
Gut hormones are peptides secreted by enteroendocrine cells in the GI tract that regulate digestion, motility, appetite, and glucose metabolism. Incretins are a specific subset — GIP and GLP-1 — that augment insulin secretion in response to oral nutrients. All incretins are gut hormones, but not all gut hormones are incretins; motilin, secretin, and ghrelin, for example, are gut hormones with non-incretin functions.
Tirzepatide is a unimolecular dual GIP/GLP-1 receptor agonist, and the GIP component appears to contribute meaningful efficacy beyond GLP-1 agonism alone. Proposed mechanisms include enhanced beta-cell glucose responsiveness, central effects on appetite regulation, and favorable remodeling of adipose tissue. SURPASS and SURMOUNT Phase 3 trials showed tirzepatide produced superior glycemic and weight-loss outcomes compared with GLP-1 monotherapy at equivalent or lower doses.
No standalone PYY3-36 therapeutic has received FDA approval as of 2026. Small clinical trials showed PYY3-36 reduces food intake but causes dose-limiting nausea at effective doses, which has held back single-agent development. The most likely future role for PYY is as a component of fixed-dose combinations or unimolecular multi-agonists with GLP-1 and other appetite-suppressing peptides — several such candidates are in preclinical and early clinical development.
Motilin and ghrelin are structurally similar peptides secreted during fasting, and their receptors are closely related. Motilin triggers Phase III contractions of the migrating motor complex, the stereotyped intestinal housekeeper wave. Ghrelin stimulates appetite and growth hormone release from the pituitary. Both are suppressed by eating, but they act on distinct receptors — motilin on the motilin receptor, ghrelin on the GHSR1a receptor — with largely non-overlapping downstream effects.
Glucagon is the primary counter-regulatory hormone to insulin, mobilizing glucose through hepatic glycogenolysis and gluconeogenesis. For patients with insulin-treated diabetes who become severely hypoglycemic and cannot safely consume oral carbohydrates, injected or intranasal glucagon rapidly raises blood glucose. Ready-to-use intranasal (Baqsimi) and prefilled injectable (Gvoke) formulations have simplified administration compared with historical reconstitution-based kits.
Yes, but primarily in observational and physiological studies rather than therapeutic trials. Circulating nesfatin-1 has been measured in obesity, type 2 diabetes, eating disorders, polycystic ovary syndrome, and pregnancy with heterogeneous results. No therapeutic nesfatin-1 agonist or antagonist has entered late-stage clinical development as of 2026. The peripheral receptor for nesfatin-1 remains unidentified, which has slowed translational pharmacology for nearly two decades.